NICE backs MabThera for first-line CLL

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of MabThera (Rituxan-U.S.) rituximab from Roche (SIX:ROG) in combination with fludarabine and cyclophosphamide for first-line treatment of chronic lymphocytic leukemia (CLL). The agency recommended against the mAb's use with other chemotherapeutics. The FAD, which is in line with a preliminary recommendation issued in March, can be found at http://www.nice.org.uk/nicemedia/pdf/FADLeukaemiaRituximab.pdf ...